Last Updated: June 25, 2026

Patent: 10,047,096

✉ Email this page to a colleague

Summary for Patent: 10,047,096

Title:	Substituted pyridobenzodiazepinone-derivatives and use thereof
Abstract:	The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
Inventor(s):	Schall; Andreas (Wuppertal, DE), Klar; Jurgen (Wuppertal, DE), Lobell; Mario (Wuppertal, DE), Schirok; Hartmut (Langenfeld, DE), Telser; Joachim (Wuppertal, DE), Muller; Steffen (Essen, DE), Brohm; Dirk (Mettmann, DE), Briem; Hans (Berlin, DE), Jori en; Hannah (Heiligenhaus, DE), Keldenich; Joerg (Berlin, DE), Bottger; Michael (Wuppertal, DE), Von Degenfeld; Georges (Leverkusen, DE), Schlange; Thomas (Haan, DE), Bomer; Ulf (Glienicke, DE), Lindner; Niels (Wuppertal, DE), Eilken; Hanna (Wuppertal, DE), Hristodorov; Dmitrij (Wuppertal, DE), Wasnaire; Pierre (Dusseldorf, DE), Gericke; Kersten Matthias (Wuppertal, DE), Barfacker; Lars (Dusseldorf, DE)
Assignee:	Bayer Pharma Aktiengesellschaft (Berlin, DE)
Application Number:	15/529,043
Patent Claims:	see list of patent claims

Details for Patent 10,047,096

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004	10,047,096	2035-11-23
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	June 30, 2006	10,047,096	2035-11-23
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	August 10, 2012	10,047,096	2035-11-23
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	October 13, 2016	10,047,096	2035-11-23
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	March 20, 2018	10,047,096	2035-11-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.